Severe proteinuria (but not being on dialysis) may be associated with initial inadequate complement inhibition and delayed hematological response to eculizumab therapy

J Nephrol. 2024 Jan;37(1):253-256. doi: 10.1007/s40620-023-01831-5. Epub 2023 Dec 22.

Authors

Marco Allinovi¹, Tommaso Mazzierli², Leonardo Caroti², Giulia Antognoli², Calogero Lino Cirami²

Affiliations

¹ Nephrology, Dialysis and Transplantation Unit, Careggi University Hospital, Florence, Italy. marco.allinovi@gmail.com.
² Nephrology, Dialysis and Transplantation Unit, Careggi University Hospital, Florence, Italy.

PMID: 38133742
DOI: 10.1007/s40620-023-01831-5

No abstract available

Keywords: Complement inhibition; Eculizumab; Hemodialysis; Thrombotic microangiopathy.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Proteinuria / drug therapy
Renal Dialysis* / adverse effects
Thrombotic Microangiopathies*

Substances

eculizumab
Antibodies, Monoclonal, Humanized